New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
14:43 EDTABMDAbiomed may have to obtain stringent approval for Impella, says Piper
Piper Jaffray predicts that Abiomed could be forced to obtain a PMA, or pre-market approval, for its Impella device. Pre-market approvals are the most stringent type of device marketing application required by the FDA, according to the agency's website. The firm thinks the company will have to conduct a series of new studies, but it maintains an Overweight rating on the stock, citing valuation. However, the firm expects the shares to remain range-bound in the near-term.
News For ABMD From The Last 14 Days
Check below for free stories on ABMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
07:14 EDTABMDAbiomed backs FY15 revenue view $205M-$212M, consensus $209.6M
Subscribe for More Information
07:12 EDTABMDAbiomed reports Q1 EPS (4c), consensus 2c
Subscribe for More Information
July 29, 2014
08:11 EDTABMDAbiomed management to meet with Benchmark
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use